Literature DB >> 22652826

Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

G Arnaldi1, T Mancini, G Tirabassi, L Trementino, M Boscaro.   

Abstract

Cushing's syndrome (CS) is a clinical condition resulting from chronic exposure to glucocorticoid excess. As a consequence, hypercortisolism contributes significantly to the early development of systemic disorders by direct and/or indirect effects. Complications such as obesity, hypertension, diabetes, dyslipidemia, and hypercoagulability cause premature atherosclerosis and increase cardiovascular mortality. Impairment of the skeletal system is a relevant cause of morbidity and disability in these patients especially due to the high prevalence of vertebral fractures. In addition, muscle weakness, emotional lability, depression, and impairment of quality of life are very common. Clinical management of these patients is complex and should be particularly careful in identifying global cardiovascular risks and aim at controlling all complications. Although the primary goal in the prevention and treatment of complications is the correction of hypercortisolism, treatment does not completely eliminate these comorbidities. Given that cardiovascular risk and fracture risk can persist after cure, early detection of each morbidity could prevent the development of irreversible damage. In this review we present the various complications of CS and their pathogenetic mechanisms. We also suggest the clinical management of these patients based on our extensive clinical experience and on the available literature.

Entities:  

Mesh:

Year:  2012        PMID: 22652826     DOI: 10.1007/BF03345431

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  185 in total

1.  Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease.

Authors:  Ulla Feldt-Rasmussen; Roger Abs; Bengt-Ake Bengtsson; Helge Bennmarker; Margareta Bramnert; Elizabeth Hernberg-Ståhl; John P Monson; Björn Westberg; Patrick Wilton; Christian Wüster
Journal:  Eur J Endocrinol       Date:  2002-01       Impact factor: 6.664

2.  Elevated cortisol levels in Cushing's disease are associated with cognitive decrements.

Authors:  M N Starkman; B Giordani; S Berent; M A Schork; D E Schteingart
Journal:  Psychosom Med       Date:  2001 Nov-Dec       Impact factor: 4.312

3.  Steroid myopathy. Clinical, histologic and cytologic observations.

Authors:  A K Afifi; R A Bergman; J C Harvey
Journal:  Johns Hopkins Med J       Date:  1968-10

4.  Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease.

Authors:  Daesman Suri; Roy E Weiss
Journal:  J Clin Endocrinol Metab       Date:  2004-12-07       Impact factor: 5.958

5.  Spontaneous recovery of bone mass after cure of endogenous hypercortisolism.

Authors:  Maria Elena Randazzo; Erika Grossrubatscher; Paolo Dalino Ciaramella; Angelo Vanzulli; Paola Loli
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

6.  Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

Authors:  K B Hansen; T Vilsbøll; J I Bagger; J J Holst; F K Knop
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

7.  The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Paolo Cappabianca; Monica De Leo; Antongiulio Faggiano; Gaetano Lombardi; Leo J Hofland; Steven W J Lamberts; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

8.  High prevalence of nodular thyroid disease in patients with Cushing's disease.

Authors:  C Invitti; R Manfrini; B M Romanini; F Cavagnini
Journal:  Clin Endocrinol (Oxf)       Date:  1995-09       Impact factor: 3.478

Review 9.  Residual symptoms in depression an emerging therapeutic concept.

Authors:  Nicoletta Sonino; Giovanni A Fava
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-05       Impact factor: 5.067

10.  Primary thyroid disorders in endogenous Cushing's syndrome.

Authors:  Hugo Niepomniszcze; Fabian Pitoia; Silvia B Katz; Raul Chervin; Oscar D Bruno
Journal:  Eur J Endocrinol       Date:  2002-09       Impact factor: 6.664

View more
  27 in total

1.  Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.

Authors:  S Cannavo; E Messina; A Albani; F Ferrau; V Barresi; S Priola; F Esposito; F Angileri
Journal:  Endocrine       Date:  2015-04-16       Impact factor: 3.633

2.  Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants.

Authors:  L Trementino; G Appolloni; L Ceccoli; G Marcelli; C Concettoni; M Boscaro; G Arnaldi
Journal:  Osteoporos Int       Date:  2013-10-15       Impact factor: 4.507

3.  Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: focus on the role of androgen receptor CAG polymorphism.

Authors:  G Tirabassi; N delli Muti; A Gioia; A Biagioli; A Lenzi; G Balercia
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

4.  The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.

Authors:  L Trementino; M Zilio; G Marcelli; G Michetti; M Barbot; F Ceccato; M Boscaro; C Scaroni; G Arnaldi
Journal:  Endocrine       Date:  2014-12-11       Impact factor: 3.633

Review 5.  Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.

Authors:  Laura Trementino; Marina Cardinaletti; Carolina Concettoni; Giorgia Marcelli; Marco Boscaro; Giorgio Arnaldi
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

6.  Peptic ulcer disease in endogenous hypercortisolism: myth or reality?

Authors:  Esra Hatipoglu; Asli Sezgin Caglar; Erkan Caglar; Serdal Ugurlu; Murat Tuncer; Pinar Kadioglu
Journal:  Endocrine       Date:  2015-04-21       Impact factor: 3.633

7.  Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease.

Authors:  Laura Trementino; Marina Cardinaletti; Carolina Concettoni; Giorgia Marcelli; Barbara Polenta; Maurizio Spinello; Marco Boscaro; Giorgio Arnaldi
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 8.  Harmful effects of functional hypercortisolism: a working hypothesis.

Authors:  Giacomo Tirabassi; Marco Boscaro; Giorgio Arnaldi
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

9.  Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.

Authors:  Armando Tripodi; Concetta T Ammollo; Fabrizio Semeraro; Mario Colucci; Elena Malchiodi; Elisa Verrua; Emanuele Ferrante; Giorgio Arnaldi; Laura Trementino; Lidia Padovan; Veena Chantarangkul; Flora Peyvandi; Giovanna Mantovani
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

10.  Possible efficacy of Lavender and Tea tree oils in the treatment of young women affected by mild idiopathic hirsutism.

Authors:  G Tirabassi; L Giovannini; F Paggi; G Panin; F Panin; R Papa; M Boscaro; G Balercia
Journal:  J Endocrinol Invest       Date:  2012-11-26       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.